External Link PDF

09-Feb-2021

Remuneration Committee Terms of Reference

09-Feb-2021

Audit Committee Terms of Reference

05-Feb-2021

Notice of Annual General Meeting

05-Feb-2021

Proxy for use at Annual General Meeting

30-Jun-2020

Redx Circular

30-Jun-2020

Redx Proxy for Use at General Meeting

30-Mar-2020

Redx Redmile Loan announcement

27-Mar-2020

Redx Pharma AGM Letter to Shareholders 2020

27-Mar-2020

Redx Pharma AGM Notice 2020

27-Mar-2020

Redx Pharma AGM Proxy 2020

06-Jan-2020

Rule 2.11 letter to employees

06-Jan-2020

Rule 2.11 letter to shareholders

06-Jan-2020

Redx – Rule 8 Response – Jan 2020

03-Jan-2020

Shareholder Circular Proposed Capitalisation of Loan

18-Jul-2019

Hardman & Co Research Note – 18 July 2019 – Pan-RAF agreement strengthens balance sheet

10-Jul-2019

Hardman & Co Research Note – 10 July 2019 – Phase I trial resumed

28-Dec-2018

Notice of AGM

30-Nov-2018

Hardman & Co Research Note – 30 Nov 2018 – RXC006: first anti-fibrosis development candidate

27-Nov-2018

Hardman & Co Research Note – 27 Nov 2018 – Streamlined, focused and good value

09-Nov-2018

Hardman & Co Research Note – 9 Nov 2018 – ROCK2 inhibitors in chronic kidney disease

02-Oct-2018

Hardman & Co Research Note – 2 Oct 2018 – Redx Pharma Strategy Launch

06-Sep-2018

Hardman & Co Research Note – 6 Sep 2018 – Back to the clinic

18-Jun-2018

Hardman & Co Research Note – “Focus, Realism and Results”

15-May-2018

Hardman & Co Research Note – Clinical and corporate update

14-Feb-2018

Hardman & Co Research Note – 14 Feb 2018 – RXC004 in the clinic

12-Feb-2018

Notice of AGM

13-Nov-2017

Hardman & Co Research Note

06-Nov-2017

Shareholder Letter

06-Nov-2017

Corporate Presentation

10-Aug-2017

The Joint Administrators’ Proposals

17-May-2017

Presentation – Interim results for the Six Months Ended 31 March 2017

03-Apr-2017

Hardman & Co research note – Gram-negative antibiotics grant

21-Mar-2017

Presentation – Final results for the year ended 30 September 2016

10-Feb-2017

Application Form for Open Share Offer

10-Feb-2017

Proxy for use at General Meeting on 28 February 2017

10-Feb-2017

Circular to Shareholders

12-Dec-2016

Hardman & Co research note – RXC005 BTK inhibitor – watch this space

08-Aug-2016

Hardman & Co research note – Advancing to clinic, increasing value

24-Feb-2016

AGM Presentation for the year to 30 September 2015

22-Jan-2016

Hardman & Co research note – Pipeline progress — Porcupine Inhibitor

27-Mar-2015

Admission to trading on AIM